Table 1 (abstract P070). See text for description
From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
| Â | FMF + Definite JSPA | FMF + Probable JSPA | FMF patients without JIA and JSpA | FMF + JIA (except ERA or JSpA) |
|---|---|---|---|---|
Patients, n | 32 | 5 | 268 | 15 |
Female, n (%) | 10 (31.25%) | 1 (20%) | 148 (55.22%) | 10 (66.66%) |
Age of disease onset, mean ±SD years | 7.19 ± 3.68 | 5.60 ± 4.93 | 4.91 ± 3.40 | 4.93 ± 3.32 |
Age at study, mean ±SD years | 14.84 ± 3.70 | 13.40 ± 1.67 | 12.51 ± 4.43 | 10.73 ± 3.57 |
M694V mutation n(%) | 19 / 30 (63.33%) | 3 (60%) | 148 / 245 (60.40%) | 11 (73.33%) |
Disease onset >6 yrs | 26 (81.25%) | 5 (100%) | Â | 6 (40%) |
Oligorthritis | 21 (65.62%) | 1 (20%) | 14 (93.33%) | |
Inflammatory back pain | 17 / 32 (53.1%) | 3 / 5(60%) | 0 (0%) | |
Enthesopathy | Â | 3 / 5(60%) | 0 (0%) | |
Sacroiliitis | 22 /32(68.7%) | 0 / 1 (0%) | 0 /5 (0%) | |
Coxofemoral Arthritis | 14 /21(66.7%) 19/32(59.37%) | 2 / 5(40%) | 0 / 15 (0%) | |
Tarsometatarsal sensivity | Â | 1 / 5(20%) | 1 / 7(14.3%) | |
HLA-B 27 Positivity | 12 / 32 (37.5%) | 0 / 1(0%) | 0 / 3(0%) | |
Male Gender | Â | 4 / 5(80%) | 5 /15(33.3%) | |
Response to NSAID | 9 / 22(40.9%) | 4 / 5(80%) | 2 / 7(28.6%) | |
Limitation in Schober test (< 4 cm) | 22 /32(68.7%) | 2 / 5(40%) | 0 / 7(0) | |
21 / 26(80.7%) | ||||
Family history of SpA group of disease, dactylitis, psoriasis or presence of IBD | 7 / 32(21.87%) | 1 / 5(20%) | 1 /8(12.5%) | |
10 / 32(31.3%) |